Heparinized Saline

Phase 2

CCorewell Health West

Heparinized Saline is one of 41 therapeutic programs targeting Pancreatic Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Pancreatic AdenocarcinomaActive, not recruiting

Pancreatic AdenocarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

47 competitors in Pancreatic Adenocarcinoma

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

45 2

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Approved

11 3

Abraxane

Bristol-Myers Squibb

Phase 3

24 4

Taxol

Eloxatin

11 6

Mfolfirinox

Incyte

Phase 3

7 7

Opdivo

Bristol-Myers Squibb

Phase 2

6 8

Imfinzi

AstraZeneca

Phase 2

4 9

Gemzar

Johnson & Johnson

Phase 2

3 10

Fudr

Pfizer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Active, not recruiting

Pancreatic Adenocarcinoma

NCT03856658

Clinical

Trials by Indication[1]

Pancreatic Adenocarcinoma1 trial

A Phase II Trial of Hepatic Artery Infusional Floxuridine With Systemic Chemotherapy in the Treatment of Pancreatic Cancer Liver Metastases

Active, not recruiting·CCorewell Health West·Phase 2·NCT03856658·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Heparinized Saline. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Heparinized Saline. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Corewell Health West company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: CCorewell Health West

Heparinized Saline

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Pancreatic Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News